-
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
NCT04370587 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
NCT06413680 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT06581406 ·
Phase: Phase 2, Phase 3 ·
Ages: No age limits stated ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT05970497 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Easton, Hershey, Philadelphia, Pittsburgh
-
A Study of VET3-TGI in Patients With Solid Tumors
NCT06444815 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
NCT07621614 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: Up to 25 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
NCT04511013 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
NCT05361174 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT06326411 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130 ·
Phase: Phase 1 ·
Ages: 16 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
NCT06624644 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
NCT03686124 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
NCT04114136 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Allentown, Bethlehem, Chambersburg, Danville
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
NCT04752826 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT05136196 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Willow Grove
-
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069 ·
Phase: Not specified ·
Ages: 40 Years to 75 Years ·
Sex: All (male and female)
· Pennsylvania: Allentown, Bethlehem, Danville, East Stroudsburg
-
DESTINY-PANTUMOUR04
NCT07124000 ·
Phase: Not specified ·
Ages: 18 Years to 130 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
NCT06599619 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
NCT03567889 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Easton, Hershey, Philadelphia
-
Evaluation of Hypoxia in Primary Melanoma
NCT06831071 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
NCT04658303 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
NCT05839912 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
NCT05896839 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Investigating Real-Time Immunotherapy Symptoms Study
NCT07280715 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT05655312 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Allentown, Bethlehem, Easton, Philadelphia
-
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
Neoadjuvant Tebentafusp for Uveal Melanoma
NCT06414590 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
NCT04903119 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Easton
-
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Broomall, Philadelphia, York
-
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
NCT07223411 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
NCT07223424 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
NCT06249048 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Project: Every Child for Younger Patients With Cancer
NCT02402244 ·
Phase: Not specified ·
Ages: Up to 25 Years ·
Sex: All (male and female)
· Pennsylvania: Allentown, Bethlehem, Danville, Hershey
-
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
NCT06216938 ·
Phase: Early Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Allentown, Philadelphia, Pittsburgh
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
NCT06060613 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
NCT05877430 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
NCT05498792 ·
Phase: Early Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
NCT03947385 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT06585410 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Hershey, Philadelphia
-
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904 ·
Phase: Phase 3 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Pennsylvania: Easton, Pittsburgh
-
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT04485013 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
NCT05549297 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
NCT06070012 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Tebentafusp-tebn With LDT in Metastatic UM
NCT06626516 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT04851119 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Months to 30 Years ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Allentown, Bethlehem, Chambersburg, Dunmore
-
The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT02000089 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180 ·
Phase: Phase 3 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh